# FRK kinase

Source: https://onco.cc/targets/frk/  
OnCo record `frk` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers.

## Summary

Fyn-related kinase (FRK) is a non-receptor tyrosine kinase of the SRC family that, unusually for the family, behaves as a tumour suppressor in several tissues: it stabilises PTEN, and its loss is reported in glioma, hepatocellular carcinoma and breast cancer. It is listed as a target of approved drugs because multi-kinase inhibitors such as dasatinib bind it, rather than because inhibiting it is the goal. Activating FRK fusions and mutations have been described in a minority of liver cancers, where kinase inhibition may be relevant.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: chembl-gap
- Symbol: FRK
- Class: kinase
- Biology: A nuclear and cytoplasmic SRC-family kinase expressed in epithelial tissues, brain and liver; it phosphorylates PTEN and retinoblastoma protein, slowing the cell cycle.
- Where found: Epithelial tissues, brain and liver; Reduced in glioma, hepatocellular carcinoma and some breast cancers

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/FRK_(gene)
- UniProt P42685: FRK: https://www.uniprot.org/uniprotkb/P42685/entry
- HGNC:3955 FRK: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3955
- ChEMBL target CHEMBL4223: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4223

## Connected records

- targets: [SRC family kinases](https://onco.cc/targets/src/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Dasatinib](https://onco.cc/drugs/dasatinib/)

---
JSON: https://onco.cc/api/v1/entities/frk.json